Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude du cathéter THERMOCOOL SMARTTOUCH Surround Flow (SF) avec le générateur TRUPULSE pour le traitement de la PAFOUS symptomatique réfractaire aux médicaments (PulseSmart)

26 octobre 2026 mis à jour par: Biosense Webster, Inc.

Évaluation de l'innocuité et de l'efficacité du cathéter THERMOCOOL SMARTTOUCH™ SF avec le générateur TRUPULSE™ pour le traitement de la fibrillation auriculaire paroxystique paroxystique (FAP) symptomatique réfractaire aux médicaments

The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

136

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Camperdown, Australie, 2050
        • Royal Prince Alfred Hospital
      • Garran, Australie, 2605
        • Canberra Heart Rhythm
      • Westmead, Australie, 2145
        • Westmead Hospital
    • Ontario
      • Newmarket, Ontario, Canada, L3Y 2P9
        • Southlake Regional Health Centre
      • Ottawa, Ontario, Canada, K1Y 4W7
        • University of Ottawa Heart Institute
    • Quebec
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre
      • Montreal, Quebec, Canada, H1T 1C8
        • Montreal Heart Institute

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria::

  • Diagnosed with Symptomatic PAF (Physician's note indicating recurrent self-terminating AF). At least one (1) electrocardiographically documented AF episode within twelve (12) months prior to enrollment. Electrocardiographic documentation may include, but is not limited to, electrocardiogram (ECG), Holter monitor, or other electrocardiographical devices accepted by investigators
  • Failed at least one (1) Class I or Class III Antiarrhythmic Drug (AAD) as evidenced by recurrent symptomatic AF or has intolerable side effects or is contraindicated to the Class I or Class III AAD
  • Able and willing to comply with all pre-procedure, post-procedure, and follow-up testing and visit requirements
  • Willing and capable of providing consent

Exclusion Criteria:

  • AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (e.g., untreated documented obstructive sleep apnea and acute alcohol toxicity)
  • Previous LA ablation or surgery
  • Patients known to require ablation outside the PV region (atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, atrial tachycardia, atrial flutter of unknown origin, ventricular tachycardia and Wolff-Parkinson-White)
  • Previously diagnosed with persistent AF (> 7 days in duration)
  • Severe dilatation of the LA (documented LAD >50mm antero-posterior diameter on imaging within 6 months prior to enrollment
  • Documented left atrium (LA) thrombus within 48 hours prior to the index procedure by Transesophageal Echocardiography (TEE), or by Intracardiac Echocardiography (ICE) prior to transeptal puncture during procedure
  • Documented severely compromised LVEF (LVEF <40%) by imaging within 6 months prior to enrollment
  • Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
  • History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • History of a documented thromboembolic event (including TIA) within the past 12 months, or history of a documented left atrial appendage (LAA) thrombus
  • History of a documented symptomatic lacunar infarction within the past 12 months
  • Previous PCI/MI within the past 2 months
  • Coronary Artery Bypass Grafting (CABG) surgery within past 6 months
  • Valvular surgery, cardiac surgery (e.g., ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
  • Unstable angina pectoris within the past 6 months
  • Anticipated cardiac transplantation, cardiac surgery or other major surgery within the next 12 months
  • Significant pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
  • Known significant PV anomaly that in the opinion of the investigator would preclude enrollment in this study
  • Has known pulmonary vein stenosis
  • Pre-existing hemi diaphragmatic paralysis
  • Acute illness, active systemic infection or sepsis
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
  • Severe mitral regurgitation (Regurgitant volume 60 mL/beat, Regurgitant fraction 50%, and/or Effective regurgitant orifice area 0.40cm^2)
  • Presence of implanted pacemaker, Implantable Cardioverter-Defibrillator (ICD), recently implanted (within 6 months) LAAO device or other implanted metal cardiac device within the cardiac space that may interfere with the energy field created during the ablation procedure.
  • Presence of a condition that precludes vascular access (such as IVC filter)
  • Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this study
  • Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
  • Current enrollment in an investigational study evaluating another device or drug
  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation
  • Life expectancy less than 12 months
  • History of massive hemorrhage within the past 6 months
  • Presenting contra-indications for the devices

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Pulsed Field (PF)/Radiofrequency (RF) Ablation System

Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation.

THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants With Primary Adverse Events (PAEs)
Délai: Up to 12 Months post ablation procedure on Day 0

An adverse event (AE) was any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including abnormal laboratory finding, in participants or users in context of clinical investigation, whether or not related to device/procedure. PAEs included the following adverse events: Device or procedure related death within 30 days of ablation procedure, esophageal perforating complications (atrio-esophageal fistula [up to 90 days post ablation procedure], esophago-pericardial fistula), myocardial infarction, cardiac tamponade/perforation up to 30 days post ablation, thromboembolism, stroke/cerebrovascular accident (CVA), transient ischemic attack (TIA), phrenic nerve paralysis, pulmonary vein stenosis (occurring anytime during 12 month follow-up period considered a PAE), major vascular access complication/bleeding, pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis.

Up to 12 Months post ablation procedure on Day 0
Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes
Délai: From Day 91 up to Day 365 post ablation procedure on Day 0

Percentage of participants with freedom from documented (symptomatic and asymptomatic) atrial arrhythmia (AF, AT or AFL) episodes based on electrocardiographic data and from all failure modes were reported. Atrial tachyarrhythmia (AF/AT/AFL of unknown origin) episodes were based on electrocardiographic data [12-lead electrocardiogram(ECG) or greater than or equal to(>=) 30 seconds on ECG or sponsor provided transtelephonic monitor (TTM) or Holter device] during effectiveness evaluation period (Day 91 to Day 365) and any of following failure modes: acute procedural, repeat ablation, non-study device, anti-arrhythmic drug (AAD), continuous AF/AT/AFL of unknown origin, and any direct current cardioversion procedure during evaluation period for documented atrial tachyarrhythmia (AF/AT/AFL of unknown origin). AFL of unknown origin was defined as all AFL except those cavotricuspid isthmus dependent AFL as confirmed by 12-Lead ECG and entrainment maneuvers in an electrophysiology (EP) study.

From Day 91 up to Day 365 post ablation procedure on Day 0

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12
Délai: Baseline, Month 12

Change from baseline in AFEQT total score at Month 12 was reported. AFEQT questionnaire was used to assess the quality-of-life post ablation procedure. The AFEQT questionnaire included 20 questions on a 7-point Likert scale. Questions 1-18 evaluated health-related quality of life (HRQoL), including AF-related symptoms (Questions 1-4), daily activities (Questions 5-12), and treatment concerns (Questions 13-18), while Questions 19-20 assessed participant satisfaction with treatment. The first 18 questions were used to calculate the overall AFEQT scores. Scores are transformed to a scale ranging from 0 to 100, where a score of 0 indicated complete disability and a score of 100 indicated no disability. Higher scores indicated improvement. The formula to calculate these scores is as follows:

100 minus([sum of severity for all questions answered minus number of questions answered]*100 divided by total number questions answered*6).

Baseline, Month 12

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

28 février 2024

Achèvement primaire (Réel)

28 octobre 2025

Achèvement de l'étude (Réel)

28 octobre 2025

Dates d'inscription aux études

Première soumission

15 février 2024

Première soumission répondant aux critères de contrôle qualité

15 février 2024

Première publication (Réel)

22 février 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

26 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner